What is Nomax?
Nomax, founded in 1982, is a pharmaceutical company with a dual focus on manufacturing its own prescription effervescent potassium supplement, Effer-K®, and partnering with other pharmaceutical firms for product development and manufacturing. The company has demonstrated consistent growth, highlighted by the construction of a new 70,000 sq ft facility in 2008, which significantly expanded its R&D and manufacturing capabilities. This expansion positions Nomax for continued strong growth in the pharmaceutical and over-the-counter (OTC) product markets.
How much funding has Nomax raised?
Nomax has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Nomax
PPP
Public-Private Partnership
What's next for Nomax?
The recent major strategic investment signals Nomax's readiness for its next phase of expansion and innovation. This capital infusion is likely to fuel further advancements in its proprietary product lines and bolster its contract manufacturing services. Nomax's long-standing history and strategic partnerships suggest a focus on scaling operations, enhancing research and development, and potentially exploring new market segments within the pharmaceutical industry.
See full Nomax company page
